RT Journal Article
SR Electronic
T1 Seroepidemiology of SARS-CoV-2 infections in an urban Nicaraguan population
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.02.25.21252447
DO 10.1101/2021.02.25.21252447
A1 González, Fredman
A1 Vielot, Nadja A.
A1 Sciaudone, Michael
A1 Toval-Ruíz, Christian
A1 Premkumar, Lakshmanane
A1 Gutierrez, Lester
A1 Cuadra, Edwing Centeno
A1 Blandón, Patricia
A1 Silva, Aravinda M. de
A1 Rubinstein, Rebecca
A1 Bowman, Natalie
A1 Becker-Dreps, Sylvia
A1 Bucardo, Filemon
YR 2021
UL http://medrxiv.org/content/early/2021/03/01/2021.02.25.21252447.abstract
AB In a Nicaraguan population-based cohort, SARS-CoV-2 seroprevalence was 34%, with higher prevalence in children compared to adults. Having a seropositive household member was associated with a two-fold probability of individual seropositivity, suggesting a role for household transmission. Co-morbidities and preventive behaviors were not associated with SARS-CoV-2 seroprevalence.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the National Institute of Allergy and Infectious Diseases (NIAID, grant number R01AI127845 to SBD, K24AI141744 to SBD). FG is supported by an international research capacity-building award from the Fogarty International Center (grant number D43TW010923).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Institutional Review Boards of the National Autonomous University of Nicaragua - León (UNAN-León acta No. 170) and the University of North Carolina at Chapel Hill (Study #: 20-2126). All adult participants provided informed consent and parental permission was required for child participation in the study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are not publicly available. Data requests may be considered at the discretion of the senior authors.